FDA rejects skin test for blocked arteries
This article was originally published in Clinica
The US FDA has rejected a 510(k) submission from Canadian company PreMD for its point-of-care skin cholesterol test for atherosclerosis (blocked arteries).
You may also be interested in...
Ipsen’s business strategy calls for accessing external innovation across its pipeline, combined with geographic expansion, realizing the unmet potential of its marketed products and business efficiencies in manufacturing and operations.
The proposal, which would increase capacity for pandemic supplies, is similar to ideas President Trump embraced pre-pandemic.
Sanofi has named the head of its new API business; Sweden's Enzymatica has hired talent from J&J and L'Oreal; and Bayer has a new transformation officer.